Pfizer and Flagship’s Quotient Therapeutics Collaborate to Identify Novel Targets for Cardiovascular and Renal Diseases

Partnership Overview:
Pfizer has partnered with Flagship Pioneering's Quotient Therapeutics to leverage Quotient's Somatic Genomics platform to identify new targets for cardiovascular and renal diseases.

Somatic Genomics Platform:
Quotient's platform focuses on somatic mutations in diseased tissues, which can reveal a broader scope of genes associated with disease phenotypes, potentially leading to transformative therapies.

Research Focus:
The collaboration will focus on two research programs to analyze somatic mutations in diseased tissue, aiming to discover and develop new treatments for cardiovascular and renal diseases.

Strategic Partnership:
This agreement is part of a broader partnership between Pfizer and Flagship Pioneering, initiated in July 2023, with a $50 million upfront contribution from each party to develop a pipeline of innovative medicines.

Pioneering Medicines:
Flagship's in-house drug development unit, Pioneering Medicines, will lead the discovery and research activities under this partnership.

Pfizer's Strategy:
This collaboration aligns with Pfizer's strategy to recalibrate its pipeline, focusing on biologics and addressing significant gaps in care for cardiovascular and renal diseases.